Back

Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size

Festanti, A.; Stanev, D.; Simillion, C.; Rodrigues, J.; Leocani, L.; Kazlauskaite, A.; Overell, J.; Lorscheider, J.; Cutter, G.; Butzkueven, H.; Craveiro, L.; Rinderknecht, M. D.

2026-09-07 neurology
10.64898/2026.09.03.26361524 medRxiv
Show abstract

In multiple sclerosis trials, event-based endpoints like the composite confirmed disability progression (cCDP) are often limited by infrequent in-clinic testing. We present a framework that converts high-frequency, remote smartphone-based gait assessments into progression events, and establishes a new composite endpoint that blends digital and clinical progression events. Evaluated in the Phase 3b CONSONANCE study (N = 667), this digitally enhanced endpoint reduced required trial sample size by 24.9% at Week 48 compared to the original cCDP. Furthermore, it achieved equivalent statistical power 24 weeks earlier (Week 72 vs Week 96), demonstrating potential to shorten trial observation periods by 25%. In conclusion, this framework provides a practical pathway to optimize clinical trial efficiency in MS and other neurological conditions, potentially reshaping the path to therapeutic innovation.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.